Paul Edward Kelly insider trades
Open-market stock purchases and sales by Paul Edward Kelly, COO at Relmada Therapeutics, Inc, from SEC Form 4 filings since Dec 14, 2015.
Track record: 69% of 16 scored buys are up 5% or more since purchase, averaging +91%.
Companies traded
- RLMD Relmada Therapeutics, Inc: 20 buys, 18 sales, last Dec 12, 2025